What is Global Medical's earnings per share (EPS)?

Global Medical (GMRE) reported diluted earnings per share of $-0.91 for fiscal year 2025. This represents a -1616.7% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Global Medical Financials

GMRE

Source SEC Filings (10-K/10-Q) Data as of Mar 31, 2026 Currency USD FYE December

This page shows Global Medical (GMRE) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI GMRE FY2025 2026-04-22

Cash generation stays sturdier than accounting profit because this asset-heavy balance sheet carries large non-cash charges and financing costs.

FY2025 shows the core mismatch clearly: a -$6.9M net loss alongside $73.6M of operating cash flow. Because depreciation remained large at about $58.0M and interest expense kept rising to $31.8M, reported earnings now understate the cash the existing asset base is still producing.

Across FY2021-FY2025, revenue increased from $115.9M to $148.2M, but financing costs rose faster, which helps explain why moderate top-line progress did not become durable profit growth. The business reads more like a mature portfolio being financed and serviced than one getting a major earnings lift from added scale, so interest cost has become a bigger swing factor than small revenue changes.

The balance sheet is not cash-rich: year-end cash was only $9.1M against $712.4M of liabilities, so liquidity depends more on recurring operating cash than on idle cash reserves. With total assets still near $1.24B, the company appears to be harvesting an existing asset base rather than materially expanding it, which makes cash conversion more informative than net income alone.

Financial Health Signals

Financial Health Score 43/100

Scored as: REITs peer group

Scored against REITs for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →

Health score ≠ stock price. This rates the quality of Global Medical's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

FFO Margin

FFO Growth

AFFO Margin

Dividend Cov.

Piotroski F-Score Partial

5/7

Global Medical passes 5 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 2 of 4 profitability signals pass, all 2 leverage/liquidity signals pass, both operating efficiency signals pass.

Earnings Quality Mixed

-10.69x

For every $1 of reported earnings, Global Medical generates $-10.69 in operating cash flow ($73.6M OCF vs -$6.9M net income). This mixed ratio suggests some earnings may rely on non-cash accounting items.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$148.2M

YoY+6.8%

5Y CAGR+9.6%

10Y CAGR+53.3%

Global Medical generated $148.2M in revenue in fiscal year 2025. This represents an increase of 6.8% from the prior year.

EBITDA

N/A

Net Income

-$6.9M

YoY-202.9%

Global Medical reported -$6.9M in net income in fiscal year 2025. This represents a decrease of 202.9% from the prior year.

EPS (Diluted)

$-0.91

YoY-1616.7%

Global Medical earned $-0.91 per diluted share (EPS) in fiscal year 2025. This represents a decrease of 1616.7% from the prior year.

Cash & Balance Sheet

Free Cash Flow

N/A

Cash & Debt

$9.1M

YoY+33.3%

5Y CAGR+10.5%

10Y CAGR-0.1%

Global Medical held $9.1M in cash against $1.2M in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

13M

YoY-1.0%

Global Medical had 13M shares outstanding in fiscal year 2025. This represents a decrease of 1.0% from the prior year.

Margins & Returns

Gross Margin

N/A

Operating Margin

N/A

Net Margin

-4.6%

YoY-9.5pp

5Y CAGR-2.0pp

10Y CAGR+73.4pp

Global Medical's net profit margin was -4.6% in fiscal year 2025, showing the share of revenue converted to profit. This is down 9.5 percentage points from the prior year.

Return on Equity

-1.4%

YoY-2.6pp

5Y CAGR-0.8pp

Global Medical's ROE was -1.4% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 2.6 percentage points from the prior year.

Capital Allocation

R&D Spending

N/A

Share Buybacks

$6.0M

Global Medical spent $6.0M on share buybacks in fiscal year 2025, returning capital to shareholders by reducing shares outstanding.

Capital Expenditures

N/A

GMRE Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	$148.2M+6.8%	$138.8M-1.6%	$141.0M+2.7%	$137.3M+18.4%	$115.9M+23.7%	$93.7M
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	N/A	N/A	N/A	N/A	N/A	N/A
SG&A Expenses	$20.0M-5.3%	$21.1M+25.3%	$16.9M+1.9%	$16.5M+0.6%	$16.5M+37.9%	$11.9M
Operating Income	N/A	N/A	N/A	N/A	N/A	N/A
Interest Expense	$31.8M+10.7%	$28.7M-7.1%	$30.9M+22.4%	$25.2M+28.1%	$19.7M+5.4%	$18.7M
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	-$6.9M-202.9%	$6.7M-69.2%	$21.7M+8.7%	$20.0M+9.0%	$18.3M+834.0%	-$2.5M
EPS (Diluted)	$-0.91-1616.7%	$0.06	$1.13+465.0%	$0.20+5.3%	$0.19+211.8%	$-0.17

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Revenue	$38.1M-0.9%	$38.4M+3.1%	$37.2M-1.9%	$38.0M+9.7%	$34.6M-1.5%	$35.2M+2.6%	$34.3M+0.1%	$34.2M
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
SG&A Expenses	$5.1M-7.4%	$5.5M+13.0%	$4.9M-19.3%	$6.0M+66.4%	$3.6M-53.0%	$7.7M+75.9%	$4.4M-4.5%	$4.6M
Operating Income	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Interest Expense	$7.2M-13.9%	$8.4M+2.8%	$8.2M+2.1%	$8.0M+11.7%	$7.2M-5.3%	$7.6M+4.6%	$7.2M+3.5%	$7.0M
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	$1.7M+126.9%	-$6.1M-21.5%	-$5.1M-964.6%	$585K-84.3%	$3.7M+27.2%	$2.9M-13.3%	$3.4M+273.7%	-$2.0M
EPS (Diluted)	$-0.06	N/A	$-0.45	$-0.01-106.3%	$0.16	N/A	$0.14+380.0%	$-0.05

GMRE Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$1.2B-1.1%	$1.3B-0.9%	$1.3B-9.0%	$1.4B+10.3%	$1.3B+14.8%	$1.1B
Current Assets	N/A	N/A	N/A	N/A	N/A	N/A
Cash & Equivalents	$9.1M+33.3%	$6.8M+433.3%	$1.3M-68.2%	$4.0M-44.3%	$7.2M+31.0%	$5.5M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	$7.2M-2.7%	$7.4M+9.8%	$6.8M-15.9%	$8.0M+32.5%	$6.1M+8.5%	$5.6M
Goodwill	$5.9M0.0%	$5.9M0.0%	$5.9M0.0%	$5.9M0.0%	$5.9M0.0%	$5.9M
Total Liabilities	$712.4M+1.7%	$700.6M+5.8%	$661.9M-11.1%	$744.2M+18.9%	$625.9M-2.7%	$643.1M
Current Liabilities	N/A	N/A	N/A	N/A	N/A	N/A
Long-Term Debt	$1.2M-92.0%	$14.4M	N/A	N/A	N/A	N/A
Total Equity	$509.8M-4.6%	$534.1M-8.5%	$583.6M-7.8%	$633.0M+1.6%	$622.8M+40.0%	$444.8M
Retained Earnings	-$350.0M-19.1%	-$293.7M-22.9%	-$239.0M-20.3%	-$198.7M-26.6%	-$157.0M-34.5%	-$116.8M

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Total Assets	$1.2B-0.4%	$1.2B-2.4%	$1.3B-1.8%	$1.3B+2.2%	$1.3B+1.0%	$1.3B+1.1%	$1.2B+0.1%	$1.2B
Current Assets	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Cash & Equivalents	$8.2M-9.9%	$9.1M+27.5%	$7.1M+8.3%	$6.6M+21.6%	$5.4M-20.6%	$6.8M+19.1%	$5.7M+15.0%	$5.0M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	$6.8M-5.9%	$7.2M-9.1%	$7.9M+1.5%	$7.8M-3.4%	$8.1M+9.2%	$7.4M-8.6%	$8.1M+0.6%	$8.1M
Goodwill	$5.9M0.0%	$5.9M0.0%	$5.9M0.0%	$5.9M0.0%	$5.9M0.0%	$5.9M0.0%	$5.9M0.0%	$5.9M
Total Liabilities	$717.4M+0.7%	$712.4M-7.2%	$767.4M-0.6%	$771.9M+5.5%	$731.5M+4.4%	$700.6M+3.3%	$678.0M+2.3%	$662.8M
Current Liabilities	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Long-Term Debt	N/A	$1.2M0.0%	$1.2M-91.9%	$14.2M-0.7%	$14.3M-1.1%	$14.4M-0.7%	$14.5M-1.0%	$14.7M
Total Equity	$500.2M-1.9%	$509.8M+5.0%	$485.3M-3.6%	$503.2M-2.7%	$517.4M-3.1%	$534.1M-1.6%	$542.6M-2.5%	$556.4M
Retained Earnings	-$360.6M-3.1%	-$350.0M-5.2%	-$332.6M-5.1%	-$316.5M-3.5%	-$305.7M-4.1%	-$293.7M-4.5%	-$281.1M-4.5%	-$268.9M

GMRE Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	$73.6M+5.1%	$70.0M+2.3%	$68.4M-10.6%	$76.5M+11.0%	$69.0M+99.8%	$34.5M
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	-$60.4M-31.5%	-$45.9M-167.9%	$67.6M+149.3%	-$137.3M+29.5%	-$194.7M+13.0%	-$223.7M
Financing Cash Flow	-$10.3M+53.1%	-$21.9M+84.8%	-$143.8M-330.4%	$62.4M-51.1%	$127.7M-33.7%	$192.7M
Dividends Paid	$5.8M0.0%	$5.8M0.0%	$5.8M0.0%	$5.8M0.0%	$5.8M0.0%	$5.8M
Share Buybacks	$6.0M	N/A	N/A	N/A	N/A	N/A

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Operating Cash Flow	$13.4M-38.3%	$21.6M+23.2%	$17.6M-20.7%	$22.1M+80.4%	$12.3M-40.2%	$20.5M+25.9%	$16.3M-13.9%	$18.9M
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	-$9.8M-245.9%	$6.7M+1059.9%	-$703K+98.2%	-$39.2M-44.1%	-$27.2M-39.4%	-$19.5M+23.4%	-$25.5M-1527.9%	$1.8M
Financing Cash Flow	-$4.4M+83.1%	-$26.3M-62.1%	-$16.2M-186.8%	$18.7M+37.7%	$13.6M+8787.6%	$153K-98.3%	$9.2M+144.2%	-$20.7M
Dividends Paid	$10.9M+651.3%	$1.5M+0.1%	$1.5M-0.1%	$1.5M+0.1%	$1.5M-0.1%	$1.5M+0.1%	$1.5M-0.1%	$1.5M
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

GMRE Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	-4.6%-9.5pp	4.8%-10.6pp	15.4%+0.8pp	14.6%-1.3pp	15.8%+18.5pp	-2.7%
Return on Equity	-1.4%-2.6pp	1.3%-2.5pp	3.7%+0.6pp	3.2%+0.2pp	2.9%+3.5pp	-0.6%
Return on Assets	-0.5%-1.1pp	0.5%-1.2pp	1.7%+0.3pp	1.4%-0.0pp	1.5%+1.7pp	-0.2%
Current Ratio	N/A	N/A	N/A	N/A	N/A	N/A
Debt-to-Equity	0.00-0.0	0.03-1.1	1.13-0.0	1.18+0.2	1.00-0.4	1.45
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	4.3%+20.4pp	-16.0%-2.4pp	-13.6%-15.1pp	1.5%-9.3pp	10.8%+2.4pp	8.4%-1.5pp	9.9%+15.6pp	-5.7%
Return on Equity	0.3%+1.5pp	-1.2%-0.2pp	-1.0%-1.2pp	0.1%-0.6pp	0.7%+0.2pp	0.5%-0.1pp	0.6%+1.0pp	-0.4%
Return on Assets	0.1%+0.6pp	-0.5%-0.1pp	-0.4%-0.5pp	0.1%-0.2pp	0.3%+0.1pp	0.2%-0.0pp	0.3%+0.4pp	-0.2%
Current Ratio	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Debt-to-Equity	1.43+1.4	0.000.0	0.00-0.0	0.030.0	0.030.0	0.030.0	0.030.0	0.03
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Similar Companies

Diversified Healthcare Tr DHC

$2.2B

Sila Realty Trust Inc SILA

$1.7B

Strawberry Field STRW

$189.2M

Ltc Properties LTC

$2.1B

Universal Health UHT

$600.7M

Frequently Asked Questions

What is Global Medical's annual revenue?

Global Medical (GMRE) reported $148.2M in total revenue for fiscal year 2025. This represents a 6.8% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Global Medical's revenue growing?

Global Medical (GMRE) revenue grew by 6.8% year-over-year, from $138.8M to $148.2M in fiscal year 2025.

Is Global Medical profitable?

No, Global Medical (GMRE) reported a net income of -$6.9M in fiscal year 2025, with a net profit margin of -4.6%.

How much debt does Global Medical have?

As of fiscal year 2025, Global Medical (GMRE) had $9.1M in cash and equivalents against $1.2M in long-term debt.

What is Global Medical's net profit margin?

Global Medical (GMRE) had a net profit margin of -4.6% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is Global Medical's return on equity (ROE)?

Global Medical (GMRE) has a return on equity of -1.4% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Global Medical's operating cash flow?

Global Medical (GMRE) generated $73.6M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Global Medical's total assets?

Global Medical (GMRE) had $1.2B in total assets as of fiscal year 2025, including both current and long-term assets.

Does Global Medical buy back shares?

Yes, Global Medical (GMRE) spent $6.0M on share buybacks during fiscal year 2025, returning capital to shareholders by reducing shares outstanding.

How many shares does Global Medical have outstanding?

Global Medical (GMRE) had 13M shares outstanding as of fiscal year 2025.

What is Global Medical's debt-to-equity ratio?

Global Medical (GMRE) had a debt-to-equity ratio of 0.00 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Global Medical's return on assets (ROA)?

Global Medical (GMRE) had a return on assets of -0.5% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Global Medical's Piotroski F-Score?

Global Medical (GMRE) has a Piotroski F-Score of 5 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Global Medical's earnings high quality?

Global Medical (GMRE) has an earnings quality ratio of -10.69x, considered mixed quality. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

How financially healthy is Global Medical?

Global Medical (GMRE) scores 43 out of 100 on our Financial Health Score, indicating moderate standing within its REITs peer group. The score is a 0-100 composite of six dimensions (FFO Margin, FFO Growth, Leverage, Interest Cov., AFFO Margin, Dividend Cov.), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.